RxDoctor Payments Data

Nicholas Bambino, MD

Gastroenterology · Cornwall, NYNPI 1417967514

Payments from drug & device makers

$830in general payments, 2019–2025

Across 36 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$156
  • Exact Sciences$144
  • Lilly USA, LLC$90
  • AbbVie$78
  • Novo Nordisk$66
  • AstraZeneca$49
  • plus $247 from 9 others

What the payments were for

  • Food & beverage$830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$830 in reported general payments places this provider in the 35th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$41,480
Medicare patients
217
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$41,904
JardianceEmpagliflozin38$39,030
EliquisApixaban15$16,876
FarxigaDapagliflozin Propanediol15$16,004
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$8,283
XareltoRivaroxaban13$8,105
Breo ElliptaFluticasone/Vilanterol11$4,365
Nebivolol Hcl43$3,527
SynthroidLevothyroxine Sodium32$3,267
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$1,933
Atorvastatin Calcium142$1,423
Pantoprazole Sodium90$1,390
Levothyroxine Sodium64$1,319
Omeprazole88$1,315
Tolterodine Tartrate ErTolterodine Tartrate16$1,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$41,90436 claims
Boehringer IngelheimJardiance$36$39,03038 claims
PfizerEliquis$156$16,87615 claims
AstraZenecaFarxiga$49$16,00415 claims
Johnson & JohnsonXarelto$21$8,10513 claims
GSKBreo Ellipta$19$4,36511 claims
AbbVieSynthroid$78$3,26732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Cornwall

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →